AstraZeneca Pharma on Friday reported a strong set of earnings for the quarter ended September 2025 (Q2 FY26), with net profit surging 41.1% year-on-year to ₹54.2 crore, compared with ₹38.4 crore in the same period last year.

Revenue from operations grew 37% to ₹559 crore, driven by strong demand across key therapeutic areas.

The company’s EBITDA rose 43.7% to ₹75.4 crore, up from ₹52.5 crore a year ago, reflecting improved operational performance and cost efficiency.

Operating margins also expanded slightly to 13.5% from 12.9% in the year-ago quarter.

Also Read : Trent Q2 Results: Tata Group retailer posts steady profit growth, revenue up 16% YoY

Ahead of the results announcement, shares of AstraZeneca Pharma India Ltd closed 1.86% lower at ₹9,012 on the NSE on Friday.

See Full Page